Pharvaris charts approval course for swelling disorder drug on Phase III win

Pharvaris will seek approval for orally administered deucrictibant XR as competition in the HAE market mounts. The company will seek approval for deucrictibant XR as competition in the HAE market mounts. Pharvaris’ drug could soon enter an increasingly competitive HAE market, if approved. Credit: Velimir Zeland / Shutterstock.com. Swiss biopharma company Pharvaris will file for US approval of deucrictibant XR in the rare swelling disorder hereditary angioedema (HAE), after the medicine met its goals in a Phase III study. This success stems from the late-stage CHAPTER-3 trial (NCT06669754), in which Pharvaris pitted a once-daily, oral dose of deucrictibant XR against…

Source: Clinical Trials Arena